NASDAQ:ARTV

Artiva Biotherapeutics Q4 2025 Earnings Report

Artiva Biotherapeutics logo
$9.40 +0.58 (+6.51%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Artiva Biotherapeutics EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.87
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Artiva Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artiva Biotherapeutics Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
Tuesday, March 10, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Artiva Biotherapeutics' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Artiva Biotherapeutics Earnings Headlines

Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's a checkpoint you skipped. The Smart Trade Options Checklist puts the 7 most important pre-trade checks on one page. Normally $29.97, it's free today. Run it in about 30 seconds before any options trade to catch the bad ones before they cost you.tc pixel
See More Artiva Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artiva Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your email.

About Artiva Biotherapeutics

Artiva Biotherapeutics (NASDAQ:ARTV) is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors. By combining gene-editing technologies with optimized cell expansion processes, the company aims to enhance tumor targeting, persistence and safety profiles. Its platform supports rapid manufacturing and scalable production, potentially enabling broader patient access and faster clinical development timelines.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Artiva Biotherapeutics operates in key biopharma hubs across North America and Europe. The company’s management team brings collective expertise in immuno-oncology, cell therapy manufacturing and clinical development, positioning Artiva to advance its candidate programs through pivotal trials and, ultimately, regulatory approval.

View Artiva Biotherapeutics Profile